InvestorsHub Logo
icon url

Grip it and Sip It

03/24/23 8:30 AM

#218815 RE: Monroe1 #218812

I love the constant “Tik Tok” euphemism! This stonk has lost 95% of its value, is on a clinical hold by the FDA, was literally issued a scathing letter by the FDA admonishing the company and ordering to cease using the words “safe” and “efficacy” when describing this water pill!

Furthermore, whatever milestones Cyrus was meant to achieve, he hasn’t because he’d be the CEO per the SEC filings! It’s nearly nine months and three months past the time they said he would/could be offered the job!

He bought $100k of stock off the company at $.26! Not on the open market…..but through a deal that already has him profiting. His stock is worth $125k now while retail is bleeding!

The former CEO has been indicted for wire fraud and stock manipulation along with the partnering CRO!

Company is hundreds of millions on debt.

Please educate some of us on “Tik Tok” because the only “boom” I see is insolvency, which the latest 10q clearly articulated is a strong possibility

What I described is reality!!
Bearish
Bearish
icon url

that_little_voice

03/27/23 10:40 AM

#218844 RE: Monroe1 #218812

It has been a while. What hold are we waiting on for again?

Here is the link from CYDY own page.
https://www.cytodyn.com/newsroom/press-releases/detail/607/cytodyn-announces-voluntary-withdrawal-of-bla-for-hiv-mdr

, "We have decided to voluntarily withdraw our BLA for the HIV-MDR population at this time only after extensive review and deliberation, including audits from three external independent regulatory quality firms



As previously discussed, we are focusing on continued development inother HIV indications, NASH, and oncology, where we have Fast Track designation for metastatic triple-negative breast cancer.



CytoDyn plans to publish soon the safety and efficacy data in which it met its primary endpoint, in its Phase 2b/3 randomized, double-blinded, placebo-controlled trial for the HIV-MDR population, in a peer-reviewed journal.



This was back in October. Did I miss the publication?